Charles River Laboratories Exec Says Continue To Expect Lower Volumes For Research Models In North America, Spending From Academic And Government Clients Has Been Constrained By Flat NIH Budgets And Slower Grant Processing; Q3 Adj EPS Expected At $2.90 - $3; Well Positioned To Support Our Acquisition Strategy, We'd Love To Be Able To Add A Couple Additional Companies To Our Portfolio